 | Up a level |
Schmidt, Amand F; Holmes, Michael V; Preiss, David; Swerdlow, Daniel I; Denaxas, Spiros; Fatemifar, Ghazaleh; Faraway, Rupert; Finan, Chris; Valentine, Dennis; Fairhurst-Hunter, Zammy; Hartwig, Fernando Pires; Horta, Bernardo Lessa; Hypponen, Elina; Power, Christine; Moldovan, Max; van Iperen, Erik; Hovingh, Kees; Demuth, Ilja; Norman, Kristina; Steinhagen-Thiessen, Elisabeth; ... (2019). Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC cardiovascular disorders, 19(1), p. 240. BioMed Central 10.1186/s12872-019-1187-z
Löwenberg, Bob; Pabst, Thomas; Vellenga, Edo; van Putten, Wim; Schouten, Harry C; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Biemond, Bart J; Gratwohl, Alois; de Greef, Georgine E; Verdonck, Leo F; Schaafsma, Martijn R; Gregor, Michael; Theobald, Matthias; Schanz, Urs; Maertens, Johan; Ossenkoppele, Gert J (2011). Cytarabine dose for acute myeloid leukemia. New England journal of medicine NEJM, 364(11), pp. 1027-36. Waltham, Mass.: Massachusetts Medical Society MMS
Löwenberg, Bob; Beck, Joachim; Graux, Carlos; van Putten, Wim; Schouten, Harry C; Verdonck, Leo F; Ferrant, Augustin; Sonneveld, Pieter; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J; Vellenga, Edo; Breems, Dimitri; de Muijnck, Hilde; Schaafsma, Ron; Verhoef, Gregor; Döhner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Ossenkoppele, Gert J; ... (2010). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), pp. 2586-91. Washington, D.C.: American Society of Hematology 10.1182/blood-2009-10-246470
Löwenberg, Bob; Ossenkoppele, Gert J; van Putten, Wim; Schouten, Harry C; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Maertens, Johan; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J; Vellenga, Edo; van Marwijk Kooy, Marinus; Verdonck, Leo F; Beck, Joachim; Döhner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Verhoef, Gregor (2009). High-dose daunorubicin in older patients with acute myeloid leukemia. New England journal of medicine NEJM, 361(13), pp. 1235-48. Waltham, Mass.: Massachusetts Medical Society MMS 10.1056/NEJMoa0901409
van den Heuvel-Eibrink, Marry M; van der Holt, Bronno; Burnett, Alan K; Knauf, Wolfgang U; Fey, Martin F; Verhoef, Gregor E G; Vellenga, Edo; Ossenkoppele, Gert J; Löwenberg, Bob; Sonneveld, Pieter (2007). CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Annals of hematology, 86(5), pp. 329-37. Berlin: Springer 10.1007/s00277-007-0269-7
